Large Insider Purchases
Institutional-Scale SEC Form 4 Buy Signals
The Signal of $1M+ Conviction
When a corporate executive invests more than $1,000,000 of their own capital into company shares, it represents the highest level of conviction. These seven-figure purchases reflect management's belief in the company's future value.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-02-21 01:11 | 2014-02-18 | FLXN | N/A | Novo A/S | 10% owner, Other | Other | BUY | $13.00 | 692,308 | $9,000,004 | 1,783,131 | +63.5% |
| 2014-02-21 05:39 | 2014-02-18 | EGRX | Eagle Pharmaceuticals, Inc. | ProQuest Associates IV LLC | 10% owner | Pharmaceutical Preparations | BUY | $15.00 | 333,333 | $4,999,995 | 4,770,828 | +7.5% |
| 2014-02-20 22:46 | 2014-02-18 | FLXN | N/A | Bolzon Bradley J PhD | Director, 10% owner | Other | BUY | $13.00 | 307,692 | $3,999,996 | 3,206,807 | +10.6% |
| 2014-02-21 05:56 | 2014-02-18 | EGRX | Eagle Pharmaceuticals, Inc. | SCHREIBER ALAIN | Director, 10% owner | Pharmaceutical Preparations | BUY | $15.00 | 333,333 | $4,999,995 | 4,770,828 | +7.5% |
| 2014-02-20 22:50 | 2014-02-18 | FLXN | N/A | COLELLA SAMUEL D | Director, 10% owner | Other | BUY | $13.00 | 307,692 | $3,999,996 | 3,206,807 | +10.6% |
| 2014-02-20 16:35 | 2014-02-19 | CNCE | N/A | TVM Life Science Ventures VI GmbH & Co KG | Director, 10% owner | Other | BUY | $14.00 | 89,000 | $1,246,000 | 378,703 | +30.7% |
| 2014-02-21 05:49 | 2014-02-18 | EGRX | Eagle Pharmaceuticals, Inc. | Moorin Jay | Director, 10% owner | Pharmaceutical Preparations | BUY | $15.00 | 333,333 | $4,999,995 | 4,770,828 | +7.5% |
| 2014-02-20 00:17 | 2014-02-14 | NRX | N/A | Seltzer Robert R. | Director, 10% owner | Other | BUY | $12.00 | 790,000 | $9,480,000 | 4,241,097 | +22.9% |
| 2014-02-20 00:16 | 2014-02-14 | NRX | N/A | Markham Richard J | Director, 10% owner | Other | BUY | $12.00 | 790,000 | $9,480,000 | 4,241,097 | +22.9% |
| 2014-02-20 00:03 | 2014-02-14 | NRX | N/A | Care Capital III LLC | Director, 10% owner | Other | BUY | $12.00 | 790,000 | $9,480,000 | 4,241,097 | +22.9% |
| 2014-02-20 00:51 | 2014-02-18 | NHF | NEXPOINT DIVERSIFIED REAL ESTATE TRUST | DONDERO JAMES D | Other | Real Estate Investment Trusts | BUY | $10.63 | 120,854 | $1,284,678 | 3,253,637 | +3.9% |
| 2014-02-19 01:04 | 2014-02-13 | NNUTU | N/A | EBRAHIMI FARHAD FRED | 10% owner | Other | BUY | $2.55 | 2,981,300 | $7,602,315 | 5,779,766 | +106.5% |
| 2014-02-13 18:53 | 2014-02-11 | EGLT | N/A | Danish Biotech SPV I P/S | 10% owner | Other | BUY | $12.00 | 239,583 | $2,874,996 | 314,574 | +319.5% |
| 2014-02-14 01:10 | 2014-02-11 | N/A | N/A | Centerbridge Credit Partners, L.P. | 10% owner, Other | Other | BUY | $117.50 | 50,000 | $5,875,000 | 1,252,892 | +4.2% |
| 2014-02-13 19:55 | 2014-02-11 | EGLT | N/A | Index Venture Associates III Ltd | 10% owner | Other | BUY | $12.00 | 370,833 | $4,449,996 | 1,007,033 | +58.3% |
| 2014-02-14 05:37 | 2013-07-30 | N/A | N/A | TURNER STEPHEN C | Director, Officer - See Remarks | Other | BUY | $112,102.00 | 448,408 | $50,267,433,616 | 2,153,372 | +26.3% |
| 2014-02-14 04:47 | 2011-12-27 | N/A | N/A | HOSTLER STANLEY | Director, Officer, 10% owner - Vice President and Secretary | Other | BUY | $1.34 | 1,776,924 | $2,373,615 | 3,049,215 | +139.7% |
| 2014-02-14 04:30 | 2011-09-30 | N/A | N/A | HARRIS LEONARD P | Director | Other | BUY | $210,614.66 | 554,001 | $116,680,730,426 | 2,160,991 | +34.5% |
| 2014-02-14 03:28 | 2011-09-30 | N/A | N/A | ANTOLINE STEVE | Director, 10% owner | Other | BUY | $0.56 | 5,769,034 | $3,207,583 | 4,565,232 | +100.0% |
| 2014-02-14 04:24 | 2013-11-01 | N/A | N/A | AUSTIN JOSIAH T | Director, 10% owner | Other | BUY | $0.50 | 5,252,556 | $2,626,278 | 6,674,725 | +369.3% |
| 2014-02-14 02:55 | 2014-02-11 | EBIO | Carisma Therapeutics Inc. | Flagship Ventures Fund 2007, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $10.00 | 378,729 | $3,787,290 | 293,268 | +100.0% |
| 2014-02-14 00:41 | 2014-02-11 | THRX | Innoviva, Inc. | GLAXOSMITHKLINE PLC | 10% owner | Pharmaceutical Preparations | BUY | $12,850,698.95 | 342,229 | $4,397,881,850,960 | 30,258,302 | +1.1% |
| 2014-02-13 03:52 | 2014-02-10 | BIOL | N/A | FEINBERG LARRY N | 10% owner | Other | BUY | $2.57 | 2,035,033 | $5,233,291 | 599,194 | +100.0% |
| 2014-02-13 01:42 | 2014-02-11 | EGLT | N/A | SEGERROS ANDREAS Rutger | Director, 10% owner | Other | BUY | $12.00 | 133,333 | $1,599,996 | 1,859,615 | +7.7% |
| 2014-02-13 01:27 | 2014-02-11 | EGLT | N/A | SUNSTONE LIFE SCIENCE VENTURES FUND II K/S | 10% owner | Other | BUY | $12.00 | 133,333 | $1,599,996 | 1,859,615 | +7.7% |
| 2014-02-13 03:25 | 2014-02-11 | EBIO | Carisma Therapeutics Inc. | JAFCO Super V3 Investment Limited Partnership | 10% owner | Pharmaceutical Preparations | BUY | $10.00 | 219,790 | $2,197,900 | 219,790 | +100.0% |
| 2014-02-13 02:36 | 2014-02-10 | ASPX | N/A | Zisson Alex | Director, 10% owner | Other | BUY | $12.00 | 83,334 | $1,000,008 | 5,166,785 | +1.6% |
| 2014-02-13 02:28 | 2014-02-10 | ASPX | N/A | Panorama Capital, L.P. | 10% owner | Other | BUY | $12.00 | 333,334 | $4,000,008 | 2,770,589 | +13.7% |
| 2014-02-13 02:31 | 2014-02-10 | ASPX | N/A | CMEA Ventures VII LP | 10% owner | Other | BUY | $12.00 | 105,561 | $1,266,732 | 96,796 | +100.0% |
| 2014-02-13 02:38 | 2014-02-10 | ASPX | N/A | Thomas, McNerney & Partners II L.P. | 10% owner | Other | BUY | $12.00 | 83,334 | $1,000,008 | 5,166,785 | +1.6% |
| 2014-02-13 00:08 | 2014-02-12 | BYI | N/A | SRINIVASAN RAMESH | Director, Officer - President & CEO | Other | BUY | $67.54 | 15,000 | $1,013,171 | 105,936 | +16.5% |
| 2014-02-13 02:26 | 2014-02-10 | ASPX | N/A | FERGUSON RODNEY A | Director, 10% owner | Other | BUY | $12.00 | 333,334 | $4,000,008 | 2,770,589 | +13.7% |
| 2014-02-13 01:56 | 2014-02-10 | GNCA | N/A | GLAXOSMITHKLINE PLC | Other | Other | BUY | $12.00 | 143,773 | $1,725,276 | 143,773 | +100.0% |
| 2014-02-13 02:00 | 2014-02-12 | ARGS | N/A | Pharmstandard International S.A. | 10% owner | Other | BUY | $8.00 | 1,275,000 | $10,200,000 | 5,983,549 | +27.1% |
| 2014-02-12 17:18 | 2014-02-11 | EPB | N/A | KINDER RICHARD D | Director, Officer - Chairman and CEO | Other | BUY | $30.04 | 100,000 | $3,003,590 | 128,000 | +357.1% |
| 2014-02-12 00:40 | 2014-02-11 | CMFN | Investcorp Credit Management BDC, Inc. | Jansen Christopher E | Director, Officer - President and Secretary | Other | BUY | $15.00 | 66,667 | $1,000,005 | 66,667 | +100.0% |
| 2014-02-12 00:23 | 2014-02-10 | EPZM | N/A | Celgene European Investment Co LLC | 10% owner | Other | BUY | $29.25 | 340,000 | $9,945,000 | 3,674,640 | +10.2% |
| 2014-02-12 00:41 | 2014-02-11 | CMFN | Investcorp Credit Management BDC, Inc. | MAUER MICHAEL | Director, Officer - Chief Executive Officer | Other | BUY | $15.00 | 67,000 | $1,005,000 | 67,000 | +100.0% |
| 2014-02-12 05:56 | 2014-02-10 | GNCA | N/A | Bitterman Kevin | Director | Other | BUY | $12.00 | 232,820 | $2,793,840 | 2,128,678 | +12.3% |
| 2014-02-12 05:49 | 2014-02-10 | GNCA | N/A | George Simeon | Director | Other | BUY | $12.00 | 143,773 | $1,725,276 | 143,773 | +100.0% |
| 2014-02-12 05:57 | 2014-02-10 | GNCA | N/A | Polaris Venture Management Co. V, L.L.C. | 10% owner | Other | BUY | $12.00 | 232,820 | $2,793,840 | 2,128,678 | +12.3% |
| 2014-02-12 00:57 | 2014-02-07 | IDTI | N/A | WATERS GREGORY L | Director, Officer - PRESIDENT & CEO | Other | BUY | $10.52 | 100,000 | $1,051,500 | 100,000 | +100.0% |
| 2014-02-12 05:49 | 2014-02-10 | GNCA | N/A | HOFFMAN STEPHEN J | Director | Other | BUY | $12.00 | 250,931 | $3,011,172 | 1,292,415 | +24.1% |
| 2014-02-12 02:19 | 2014-02-10 | ASPX | N/A | Flynn James E | 10% owner, Other | Other | BUY | $12.00 | 700,000 | $8,400,000 | 796,591 | +724.7% |
| 2014-02-11 00:27 | 2014-02-06 | HOLX | HOLOGIC INC | MACMILLAN STEPHEN P | Director, Officer - President and CEO | X-Ray Apparatus & Tubes & Related Irradiation Apparatus | BUY | $20.78 | 198,900 | $4,133,639 | 198,900 | +100.0% |
| 2014-02-11 02:34 | 2014-02-07 | PDI | PIMCO Dynamic Income Fund | GROSS WILLIAM H | Other | Other | BUY | $30.67 | 100,000 | $3,066,970 | 200,000 | +100.0% |
| 2014-02-10 20:50 | 2014-02-07 | MUR | MURPHY OIL CORP | DEMING CLAIBORNE P | Director | Crude Petroleum & Natural Gas | BUY | $56.67 | 30,000 | $1,700,184 | 1,619,538 | +1.9% |
| 2014-02-11 02:46 | 2014-02-06 | REGN | REGENERON PHARMACEUTICALS, INC. | Sanofi | 10% owner | Pharmaceutical Preparations | BUY | $286.78 | 168,511 | $48,325,837 | 16,749,620 | +1.0% |
| 2014-02-11 00:52 | 2014-02-10 | CNX | CNX Resources Corp | CARPENTER ALVIN R | Director | Crude Petroleum & Natural Gas | BUY | $36.71 | 30,000 | $1,101,300 | 34,584 | +654.5% |
| 2014-02-07 21:14 | 2014-02-05 | TRVN | Trevena, Inc. | Forest Laboratories Holdings Ltd | 10% owner | Pharmaceutical Preparations | BUY | $7.00 | 428,571 | $2,999,997 | 3,393,466 | +14.5% |
Institutional Conviction in Form 4
Tracking these institutional-scale purchases allows you to follow the "smart money" when their conviction is highest. When an executive or a 10% beneficial owner commits a seven-figure sum to an open-market transaction, it bypasses the routine noise of stock-based compensation. These trades are often a precursor to major corporate developments or a signal that management views the current market valuation as significantly disconnected from the company’s internal growth trajectory. By monitoring these high-value entries, investors can align their portfolios with the capital of those who possess the most intimate understanding of a business's long-term health and potential.
Filtering the Market Noise
Our platform is designed to eliminate the noise and focus strictly on high-impact accumulation from directors and CEOs betting big on their company’s future. The SEC EDGAR database is frequently flooded with thousands of automated Form 4 filings, many of which involve small, technical, or pre-scheduled trades that offer little predictive value for the average investor. By applying a strict $1,000,000 minimum threshold, we isolate the transactions where insiders are taking substantial personal financial risk. This high-conviction filter serves as a powerful transparency tool, identifying the exact moments when corporate leadership moves away from passive ownership toward aggressive capital deployment.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.